Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

Journal of Physiology

Volumn 586, Issue 6, 2008, Pages 1503-1508

  Dölen, Gül ^a,b   Bear, Mark F ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FRAGILE X MENTAL RETARDATION PROTEIN; METABOTROPIC RECEPTOR 5; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT;

AUTISM; COGNITIVE DEFECT; CONFERENCE PAPER; DENDRITIC SPINE; DOWN REGULATION; EPILEPSY; EYE DOMINANCE; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; GENE TARGETING; GENOTYPE; GROWTH DISORDER; HUMAN; LEARNING; MACROORCHIDISM; MENTAL DEFICIENCY; NERVE CELL PLASTICITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SPATIAL MEMORY; ARTICLE; CELL STRUCTURE; GENE MUTATION; GROWTH; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; NEUROPATHOLOGY; VISUAL CORTEX;

ANIMALS; BRAIN; FRAGILE X SYNDROME; MICE; MICE, KNOCKOUT; NEURONS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 40949090052     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2008.150722     Document Type: Conference Paper

References (48)

1. Bear MF, Huber KM & Warren ST (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci 27, 370-377.
2. Bernardet M & Crusio WE (2006). Fmr1 KO mice as a possible model of autistic features. Scientific World Journal 6, 1164-1176.
3. Bradbury MJ, Campbell U, Giracello D, Chapman D, King C, Tehrani L, Cosford ND, Anderson J, Varney MA & Strack AM (2005). Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J Pharmacol Exp Ther 313, 395-402.
4. Chapman AG, Nanan K, Williams M & Meldrum BS (2000). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39, 1567-1574.
5. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F & Conquet F (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4, 873-874.
6. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ & Greenough WT (1997). Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proc Natl Acad Sci U S A 94, 5401-5404.
7. Conn PJ & Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37, 205-237.
8. Consortium (The Dutch-Belgian Fragile X Consortium) (1994). Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 78, 23-33.
9. Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H & Brown WT (2000). Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 100, 423-429.
10. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S & Bear MF (2007). Correction of Fragile X Syndrome in mice. Neuron 56, 955-962.
11. Dudek SM & Bear MF (1989). A biochemical correlate of the critical period for synaptic modification in the visual cortex. Science 246, 673-675.
12. Godfraind JM, Reyniers E, De Boulle K, D'Hooge R, De Deyn PP, Bakker CE, Oostra BA, Kooy RF & Willems PJ (1996). Long-term potentiation in the hippocampus of fragile X knockout mice. Am J Med Genet 64, 246-251.
13. Hagerman RJ & Hagerman PJ (2002). Fragile X Syndrome: Diagnosis, Treatment, and Research. The Johns. Hopkins University Press.
14. Harris KM & Stevens JK (1989). Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: Serial electron microscopy with reference to their biophysical characteristics. J Neurosci 9, 2982-2997.
15. Hensch TK & Stryker MP (1996). Ocular dominance plasticity under metabotropic glutamate receptor blockade. Science 272, 554-557.
16. Huber KM, Gallagher SM, Warren ST & Bear MF (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 99, 7746-7750.
17. Huber KM, Kayser MS & Bear MF (2000). Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288, 1254-1257.
18. Huber KM, Sawtell NB & Bear MF (1998). Effects of the metabotropic glutamate receptor antagonist MCPG on phosphoinositide turnover and synaptic plasticity in visual cortex. J Neurosci 18, 1-9.
19. Irwin SA, Galvez R & Greenough WT (2000). Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10, 1038-1044.
20. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST & Feng Y (2001). The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucl Acids Res 29, 2276-2283.
21. Loesch DZ, Huggins RM & Hoang NH (1995). Growth in stature in fragile X families: A mixed longitudinal study. Am J Med Genet 58, 249-256.
22. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM & Roder JC (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17, 5196-5205.
23. Marino MJ & Conn PJ (2006). Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 6, 98-102.
24. Marin-Padilla M (1972). Structural abnormalities of the cerebral cortex in human chromosomal aberrations: A Golgi study. Brain Res 44, 625-629.
25. Merlin LR, Bergold PJ & Wong RK (1998). Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J Neurophysiol 80, 989-993.
26. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R & Oostra BA (2000). Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41, 19-23.
27. Musumeci SA, Colognola RM, Ferri R, Gigli GL, Petrella MA, Sanfilippo S, Bergonzi P & Tassinari CA (1988). Fragile-X syndrome: A particular epileptogenic EEG pattern. Epilepsia 29, 41-47.
28. Naie K & Manahan-Vaughan D (2004). Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex 14, 189-198.
29. Naie K & Manahan-Vaughan D (2005). Investigations of the protein synthesis dependency of mGluR-induced long-term depression in the dentate gyrus of freely moving rats. Neuropharmacology 49, 35-44.
30. Nielsen KB, Tommerup N, Dyggve HV & Schou C (1982). Macroorchidism and fragile X in mentally retarded males. Clinical, cytogenetic, and some hormonal investigations in mentally retarded males, including two with the fragile site at Xq28, fra(X)(q28). Hum Genet 61, 113-117.
31. Nosyreva ED & Huber KM (2006). Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 95, 3291-3295.
32. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ & Warren ST (1999). Fragile X mouse: Strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94, 185-192.
33. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT & Nelson DL (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822.
34. Power AE, Berlau DJ, McGaugh JL & Steward O (2006). Anisomycin infused into the hippocampus fails to block 'reconsolidation' but impairs extinction: The role of re-exposure duration. Learn Mem 13, 27-34.
35. Qin M, Kang J, Burlin TV, Jiang C & Smith CB (2005a). Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. J Neurosci 25, 5087-5095.
36. Qin M, Kang J & Smith CB (2005b). A null mutation for Fmr1 in female mice: Effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 135, 999-1009.
37. Raymond CR, Thompson VL, Tate WP & Abraham WC (2000). Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci 20, 969-976.
38. Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR & Bear MF (2001). Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci 4, 1079-1085.
39. Steward O & Schuman EM (2003). Compartmentalized synthesis and degradation of proteins in neurons. Neuron 40, 347-359.
40. Storto M, Sallese M, Salvatore L, Poulet R, Condorelli DF, Dell'Albani P, Marcello MF, Romeo R, Piomboni P, Barone N, Nicoletti F & De Blasi A (2001). Expression of metabotropic glutamate receptors in the rat and human testis. J Endocrinol 170, 71-78.
41. Taha S & Stryker MP (2002). Rapid ocular dominance plasticity requires cortical but not geniculate protein synthesis. Neuron 34, 425-436.
42. van den Pol AN, Romano C & Ghosh P (1995). Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. J Comp Neurol 362, 134-150.
43. Vanderklish PW & Edelman GM (2002). Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci U S A 99, 1639-1644.
44. Wallace W & Bear MF (2004). A morphological correlate of synaptic scaling in visual cortex. J Neurosci 24, 6928-6938.
45. Weiler IJ & Greenough WT (1993). Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A 90, 7168-7171.
46. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J & Greenough WT (1997). Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A 94, 5395-5400.
47. Whitlock JR, Heynen AJ, Shuler MG & Bear MF (2006). Learning induces long-term potentiation in the hippocampus. Science 313, 1093-1097.
48. Yan QJ, Rammal M, Tranfaglia M & Bauchwitz RP (2005). Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066.